Journal article
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Abstract
BACKGROUND: Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activity of margetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with HER2-positive gastro-oesophageal adenocarcinoma.
METHODS: CP-MGAH22-05 was a single-arm, …
Authors
Catenacci DVT; Kang Y-K; Park H; Uronis HE; Lee K-W; Ng MCH; Enzinger PC; Park H; Gold PJ; Lacy J
Journal
The Lancet Oncology, Vol. 21, No. 8, pp. 1066–1076
Publisher
Elsevier
Publication Date
August 2020
DOI
10.1016/s1470-2045(20)30326-0
ISSN
1470-2045